Monthly Archives: November 2022

Alternative Cancer Treatment, Cancer Treatment, Cancer Vaccine, Immuno-Oncology, Immunotherapy, Uncategorized

Nicotine Dependence May Be a First Pathway to Lung Cancer

Lung cancer is one of the most common types of cancers in the U.S., as well as a top cause of preventable cancer death. Although anyone can develop this type of cancer, certain individuals have a higher risk. Those who smoke or have nicotine dependence face a considerably increased risk of having lung cancer.

With more research focusing on improving outcomes for lung cancer through cancer immunotherapy and other treatment methods, scientists need to learn more about the causes of this disease. A research team at Dartmouth’s Geisel School of Medicine studied potential pathways that lead to lung cancer.

Nicotine Dependence as a Pathway

Researchers studied possible pathways that allow a chromosome called 15q25.1 to raise an individual’s risk of lung cancer. This chromosome has previously been identified as a genetic component that can increase lung cancer risks in some individuals. The research team found two pathways associated with this chromosome that could help explain how it leads to a higher lung cancer risk.

Nicotine dependence is linked to the first pathway that the researchers found. This finding has helped scientists better understand how lung cancer develops and why individuals with a history of smoking and certain genetic components face a significantly higher risk of having lung cancer. The second pathway is linked to biological processes, including those involving the immune system.

Improved Lung Cancer Treatments

The findings of this research could pave the way for improved treatments for lung cancer. Scientists can use these findings to come up with ways to block risky genetic variants, resulting in better outcomes for those with cancer. The results of this study might also be used to develop more effective ways to treat lung cancer using the body’s immune system or other methods.

For more information on cancer treatment and cancer immunotherapy, please contact Issels® today.

Cancer Treatment, Cancer Vaccine, Immuno-Oncology

Low Fat Diets – Can They Help Prolong Life with Breast Cancer

A study by Dr. Rowan Chlebowski, a medical oncologist at Harbor-UCLA Medical Center’s Los Angeles Biomedical Research Institute, shows that some women diagnosed with breast cancer who maintain a low-fat diet may reduce their risk of early death.

Research for women in the early stages of breast cancer specific to estrogen receptor-negative (ER-negative) cancer showed positive results. For this group, Dr. Chlebowski’s study showed a reduced risk of death factor of 36 percent over a 15-year study for patients who maintained a diet of low-fat food for five years after being diagnosed.

For women diagnosed with both ER-negative and progesterone-receptor negative (PR-negative) cancer, the results were even higher. Following the same five year low-fat diet regimen after initial diagnosis, patients experienced a 56 percent reduction in risk of death due to any cause.

The study included over 2,400 women ranging in age from 48 to 79 in the early stages of breast cancer. Of the 2,400 women, approximately 1,600 were diagnosed with ER-positive cancer while the remaining 800 were diagnosed with ER-negative or both ER and PR-negative cancer.

During the study, low-fat diets for half of the women was a requirement. Unannounced checks were made throughout the study. The other group was not required to maintain a low-fat diet. The study showed a lower death rate in the low-fat diet research group.

The study is the first where a low-fat diet over an extended period for cancer patients has been researched.

For information about how the Issels integrative immuno-oncology works in the treatment of breast cancer, contact Issels®. Established in 1951, Issels® has made a name for itself internationally for its success in the long-term remission of advanced tumors.